Description
This product is a linearized polyethyleneimine (Polyethylenimine Linear, PEI) specially developed for the large-scale production of AAV in suspension culture systems. It is a chemically synthesized product, free of animal-derived components, with low cytotoxicity. The product is provided in sterile liquid form and has a wide applicability for various AAV serotypes. It features strong DNA loading capacity, low transfection complex ratio, and high complex stability, facilitating large-scale AAV and protein production.
Features
- Optimized for AAV Manufacturing: Specially developed for large-scale recombinant AAV production in suspension 293 cell lines.
- Superior Packaging Efficiency: Achieves a doubled full capsid ratio with 10× higher efficiency compared to standard PEI.
- Reduced Reagent Usage: Delivers equivalent transfection efficiency with just 1/4 the amount of PEI, cutting reagent input in half.
- Cost-Effective: Lower consumption directly reduces overall production cost.
- High Transfection Performance: Ensures robust and reliable transfection across a wide range of applications.
- Regulatory Advantage: GMP-ready with DMF filing support, accelerating project approval and commercialization.
Applications
- Production of AAV/LV Viral Vectors
- Protein production
Specifications
|
Form |
liquid |
|
Properties |
Polyethylenimine Linear (PEI) |
|
Virus Type |
AAV |
Components
|
Components No. |
Name |
40823ES01 |
40823ES03 |
40823ES10 |
40823ES60 |
|
40823 |
Hieff Trans™ UltraAAV Transfection Reagent |
100 μL |
1 mL |
10 mL |
100 mL |
Shipping and Storage
Hieff Trans™ UltraAAV Transfection Reagent products should be stored at 2-8℃ for 2 year.
Figures
1. Cost-Efficient & Minimal Reagent Use
Figure 1. Hieff Trans™ UltraAAV achieves more with less—minimizing reagent input while maximizing protein production efficiency.
Figure 2. Comparison of transfection performance between Yeasen Hieff TransTM (PEI AAV) and Control PEI(FectorVIR-AAV).
Hieff TransTM requires only half the reagent input yet still achieves higher viral yield than Control PEI. At equivalent viral production, the cost of transfection reagent is reduced by 50%.
Figure 3. Hieff Trans™ UltraAAV maximizes AAV yield across multiple serotypes.
Superior transfection efficiency was observed compared with leading PEIs. AAV2, AAV5, AAV8, and AAV9 were produced in suspension 293F cells using 1 µg DNA per million cells. Viral particles were harvested 72 hours post-transfection, and supernatants were analyzed.
4. Strong Stability
Figure 4. Stability evaluation in the AAV9 project.
Hieff TransTM demonstrated consistent performance across three GMP-grade batches and passed both accelerated and transport stability testing, ensuring reliable and stable supply.
Related Reading
Revolutionary PEI-Mediated Gene Delivery for Superior Transfection Efficiency
Documents:
Safety Data Sheet
Manuals
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.
Inquiry
You may also like
FAQ
The product is for research purposes only and is not intended for therapeutic or diagnostic use in humans or animals. Products and content are protected by patents, trademarks, and copyrights owned by Yeasen Biotechnology. Trademark symbols indicate the country of origin, not necessarily registration in all regions.
Certain applications may require additional third-party intellectual property rights.
Yeasen is dedicated to ethical science, believing our research should address critical questions while ensuring safety and ethical standards.